Pharmacology of neuroendocrine peptides
神经内分泌肽的药理学
基本信息
- 批准号:7429659
- 负责人:
- 金额:$ 38.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-06-01 至 2010-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAgonistAmino Acid SequenceAmino AcidsAntibodiesBindingBiologicalBiological AssayCRF receptor type 2CalcitoninCardiovascular systemChemicalsClassCollaborationsComputer SimulationConsensusCorticotropin-Releasing HormoneCorticotropin-Releasing Hormone ReceptorsDipeptidesDiureticsDrug KineticsEnd PointEndocrineEtiologyExtracellular DomainG Protein-Coupled Receptor GenesGastric Inhibitory PolypeptideGlucagonHormonesImmuneInvestigationLaboratoriesLeadLettersLigand BindingLigandsLigationMammalsMental DepressionModelingMolecular ConformationMono-SMutateNeurosecretory SystemsParathyroid HormonesPeptide SynthesisPeptidesPeripheralPharmacologic SubstancePharmacologyPhysiologicalProtein FragmentPurposeReagentReportingResearchResearch PersonnelRoleSecretinSideSomatotropin-Releasing HormoneSpecificityStimulusStressStructureStructure-Activity RelationshipTraceraminoprolineanalogastressin Bbasedesigngastrointestinal functiongastrointestinal systemhuman PTH proteininsightnovelpeptide analogpeptide structurepharmacophorepituitary adenylate cyclase activating polypeptideprogramsreceptorresponsetoolurocortin
项目摘要
Peptidic antagonists of corticotropin releasing factor (CRF) and the urocortins (Ucn) have been critical in the understanding of endocrine, immune, cardiovascular and gastrointestinal functions in response to different stress stimuli. Nonpeptide CRF antagonists are developed for the treatment of depression. Further, the actual function, distribution and specificity of the two different CRF receptors (CRFR1 and CRFR2) and their subtypes are now better understood due to the availability of CRF-receptor-selective agonists and antagonists. However, significant amino acid sequence differences between the multiple CRF native ligands (CRF and
Ucn 1, 2 and 3 in mammals) and the wide distribution of CRFR1 and CRFR2 with their concomitant modulation of multiple functions remain to be integrated and understood. There are two complementary end points to this Project: a) structural and b) pharmacological/biological. Both end points depend heavily on the synthesis of peptides (SPPS) and proteins (fragment chemical ligation). a) We propose to design and synthesize CRF/Ucn analogs and extra cellular domains 1 (ECD1s) of class B1 GPCR for functional and structural investigations using NMR in collaboration with Dr. Riek's project. Preliminary results have yielded a model of the interaction between the ECD1 of CRFR2 and the CRF antagonist, astressin B. Additional studies are
mandatory to identify the actual contact points between ligands and the respective ECDs1 responsible for the initial steps of recognition and binding. This will be achieved with binding assays of mutated ECD1s and complementarily derivatized analogs of selected ligands. From these studies, we will derive consensus bioactive/binding conformations of the CRFR1 -selective and CRFR2-selective ligands and the pharmacophores of the respective receptors, b) We will use these pharmacophores in models for the rational design of novel peptide and nonpeptide CRFR1 and CRFR2 ligands. In particular, we propose to pursue the design of peptide CRFR1-selective antagonists using several approaches distinct from that used for the
characterization of stressing a potent and CRFR1-selective agonist and astressin2-B, a potent and long acting CRFR2-selective antagonist. We will use these selective and potent reagents to identify through collaborations within this Program Project, and with outside investigators, the etiology of pathophysiological states for possible treatment.
促肾上腺皮质激素释放因子(CRF)和尿皮质素(Ucn)的肽类拮抗剂在了解不同应激刺激下的内分泌、免疫、心血管和胃肠道功能方面发挥了重要作用。非肽CRF拮抗剂是为治疗抑郁症而开发的。此外,由于CRF受体选择性激动剂和拮抗剂的可用性,两种不同的CRF受体(CRFR1和CRFR2)及其亚型的实际功能、分布和特异性现在得到了更好的了解。然而,多个CRF天然配体(CRF和CRF)之间的氨基酸序列存在显著差异
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEAN E RIVIER其他文献
JEAN E RIVIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEAN E RIVIER', 18)}}的其他基金
CORE--CHARACTERIZATION AND SYNTHESIS OF NOVEL CONOTOXINS
核心——新型芋螺毒素的表征与合成
- 批准号:
6610801 - 财政年份:2003
- 资助金额:
$ 38.05万 - 项目类别:
CORE--CHARACTERIZATION AND SYNTHESIS OF NOVEL CONOTOXIN PEPTIDES
核心——新型芋螺毒素肽的表征与合成
- 批准号:
6564577 - 财政年份:2002
- 资助金额:
$ 38.05万 - 项目类别:
Somatostatin Receptor-Selective Agonists and Antagonists
生长抑素受体选择性激动剂和拮抗剂
- 批准号:
6887348 - 财政年份:2002
- 资助金额:
$ 38.05万 - 项目类别:
Somatostatin Receptor-Selective Agonists and Antagonists
生长抑素受体选择性激动剂和拮抗剂
- 批准号:
6473846 - 财政年份:2002
- 资助金额:
$ 38.05万 - 项目类别:
Somatostatin Receptor-Selective Agonists and Antagonists
生长抑素受体选择性激动剂和拮抗剂
- 批准号:
6786662 - 财政年份:2002
- 资助金额:
$ 38.05万 - 项目类别:
CORE--SOLID PHASE PEPTIDE SYNTHESIS AND HPLC/CZE
核心--固相肽合成与HPLC/CZE
- 批准号:
6577255 - 财政年份:2002
- 资助金额:
$ 38.05万 - 项目类别:
Somatostatin Receptor-Selective Agonists and Antagonists
生长抑素受体选择性激动剂和拮抗剂
- 批准号:
7071152 - 财政年份:2002
- 资助金额:
$ 38.05万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 38.05万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 38.05万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 38.05万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 38.05万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 38.05万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 38.05万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 38.05万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 38.05万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 38.05万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 38.05万 - 项目类别: